Previous 10 | Next 10 |
Baird has initiated Vor Biopharma (VOR -2.2%) with a buy rating citing the potential of VOR33 for acute myeloid leukemia ("AML"). The firm has a $38 price target and (193% upside). Analyst Jack Allen said that he expects data on VOR33 due in 1H 2022 will be positive, leading shares higher. Al...
Cowen has initiated Vor Biopharma (VOR -2.2%) with a buy rating citing the potential of VOR33 for acute myeloid leukemia ("AML"). The firm has a $38 price target and (193% upside). Analyst Jack Allen said that he expects data on VOR33 due in 1H 2022 will be positive, leading shares higher. Al...
Gainers: Biofrontera (NASDAQ:BFRI) +36%. CF Acquisition (NASDAQ:CFVIU) +19%. Day One (NASDAQ:DAWN) +16%. Terns Pharmaceuticals (NASDAQ:TERN) +15%. Duluth Holdings (NASDAQ:DLTH) +15%. Snowflake (NYSE:SNOW) +14%. Aurinia Pharmaceuticals (NASDAQ:AUPH) +14%. Express (NYSE:EXPR) +13%. Vor Biopharm...
Oppenheimer has initiated Vio Biopharma (NASDAQ:VOR) with a buy given the potential of its engineered hematopoietic stem cells in treating hematological malignancies. The firm has a $30 price target (165% upside) Analyst Matthew Biegler sees promise on VOR33 in combination with Mylotarg (gemt...
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating in a fireside chat at the JMP Securities Hema...
CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating at the Piper Sandler 33rd Virtual Annual Heal...
Vor Biopharma (NASDAQ:VOR): Q3 GAAP EPS of -$0.50 beats by $0.12. Press Release Cash, cash equivalents and investments were $226 million as of September 30, 2021, which is anticipated to fund operations into mid-2023. For further details see: Vor Biopharma EPS beats by $0.12
VOR33 on track with initial clinical data expected in the first half of 2022 Announced pipeline expansion with first multi-targeted Treatment System simultaneously targeting CD33 and CLL-1 for AML CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq:...
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel cell therapy platform at the Society for Immunotherapy of Cancer (SITC) 36 th Annual Meeting...
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor’s President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vor’s Chief Financial Officer, will...
News, Short Squeeze, Breakout and More Instantly...
On-track for trem-cel and VCAR33 ALLO clinical updates in the second half of 2024 Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWI...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...